107 related articles for article (PubMed ID: 38781542)
1. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
Waters R; Sewastjanow-Silva M; Yamashita K; Abdelhakeem A; Iwata KK; Moran D; Elsouda D; Guerrero A; Pizzi M; Vicentini ER; Shanbhag N; Ta A; Chatterjee D; Ajani JA
JCO Precis Oncol; 2024 May; 8():e2300543. PubMed ID: 38781542
[TBL] [Abstract][Full Text] [Related]
2. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
[TBL] [Abstract][Full Text] [Related]
3. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract][Full Text] [Related]
4. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
7. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
[TBL] [Abstract][Full Text] [Related]
9. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
[TBL] [Abstract][Full Text] [Related]
11. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
12. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
13. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
14. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
16. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
17. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
18. A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal
Adeshuko FA; Squires MH; Poultsides G; Pawlik TM; Weber SM; Schmidt C; Votanopoulos K; Fields RC; Maithel SK; Cardona K
Am Surg; 2017 Jan; 83(1):82-89. PubMed ID: 28234131
[TBL] [Abstract][Full Text] [Related]
19. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]